AFT agrees distribution for Crystaderm in China

AFT Pharmaceuticals Limited,
Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com








09 July 2024
AFT agrees distribution for Crystaderm in China
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today announces an agreement
with Hainan Haiyao Co. Ltd (Shenzhen Stock Exchange SZ:000566) to distribute
Crystaderm® cream in China, the second largest pharma market in the world
1
.
Crystaderm cream is a proprietary product that treats skin infections by the
slow release of hydrogen peroxide onto the skin as an alternative to topical
antibiotics, which if misused risk development of drug resistant bacteria
2
.

AFT Pharmaceuticals Managing Director Dr Hartley Atkinson said: “We are
excited to announce our partnership with Haiyao, an established
pharmaceutical distribution company in China.
“We anticipate the launch will occur during this calendar year and believe
that that there is a significant potential for this product in such a large
population base.”
Hayao Pharmaceuticals Chairman Mr. Wang Jianping stated: “We are
delighted to partner with AFT to bring Crystaderm to Chinese consumers. There
has been an unmet clinical demand in the Chinese acne market for a long
time. As a new acne drug and anti-infective product without hormones and
antibiotics, Crystaderm has been proven to be effective. Haiyao will carry out
the commercialization process of Crystaderm in China. We are excited about
its potential and developing our relationship with AFT.”

For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial
Officer.

For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

Footnotes
1.https://www.statista.com/statistics/245473/market-share-of-the-leading-10-global-
pharmaceutical-markets/

AFT Pharmaceuticals Limited,
Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

2. Williamson DA et al (2015) NZMJ, 128 (1426) : 103-9

About AFT Pharmaceuticals
AFT is a growing New Zealand based multinational pharmaceutical company that
develops, markets, and distributes a broad portfolio of pharmaceutical products
across a wide range of therapeutic categories which are distributed across all major
pharmaceutical distribution channels: over the counter (OTC), prescription and
hospital. Our product portfolio comprises both proprietary and in-licensed products,
and includes patented, branded, and generic drugs
1
. Our business model is to
develop and in-license products for in our markets of Australia, New Zealand,
Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland and UK, and to out-
license our products to local licensees and distributors to over 125 countries around
the world. For more information about the company, visit our website
www.aftpharm.com.

About Hainan Haiyao
Hainan Haiyao Co., Ltd., a well-established Chinese pharmaceutical company, was
founded in 1965. It is the first batch of listed pharmaceutical manufacturing enterprises
in China and the first listed company in the pharmaceutical industry in Hainan
Province. The company's main products cover intermediates, APIs, chemical
innovative drugs, modern traditional Chinese medicine, biopharmaceuticals, cellular
immunity, high-end medical devices, and other fields. A number of core drugs such
as high value-added generic drugs and characteristic drugs have high popularity in
the industry. There are multiple best-selling varieties nationwide and they are exported
to dozens of countries and regions.